Key result
Cardiac contractility modulation was implanted for the first time in a human patient with dilated cardiomyopathy-related laminopathy.
Case Report (n=1)
This report describes the first human implant of cardiac contractility modulation in a patient with dilated cardiomyopathy-related laminopathy.
First CCM implant in laminopathy DCM suggests feasibility; hypothesis-generating with prospective trials needed before broader use.
Dilated cardiomyopathy (DCM)-related laminopathy (LMNA) is an inherited cardiomyopathy characterized by a higher rate of life-threatening arrhythmias and heart failure (HF) with respect to other heart diseases.1,2 LMNA mutations are found in 6% of all DCM cases and are associated with potential biventricular enlargement and systolic dysfunction. HF becomes apparent 15–20 years after the diagnosis and is associated with a high mortality rate (12%). The onset age of HF3,4 is around 30 in 10% of patients and 50 in 64% of patients.
No takes yet. Share an insight, caveat, or question.
D’Onofrio et al. (2023) conducted a case report in Dilated cardiomyopathy-related laminopathy (n=1). Cardiac contractility modulation was evaluated. Cardiac contractility modulation was implanted for the first time in a human patient with dilated cardiomyopathy-related laminopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: